<p>雅培（Abbott Laboratories，ABT）开盘下跌 4.34%。医疗服务与设备行业下跌 3.44%。该公司表现不及行业。该行业成交额前 3 的股票：Hims &amp; Hers Health Inc（HIMS）上涨 5.60%；雅培（ABT）下跌 4.34%；Danaher Corp（DHR）下跌 1.20%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png"/></p>
<h2>今天是什么原因导致雅培（ABT）股价下跌？</h2>
<p>雅培的股票今天承受了下行压力，主要是由于修订后的全年收益展望。公司下调了 2026 年的调整后摊薄每股收益指引，表明其最近收购癌症诊断公司精密科学（Exact Sciences）对业绩的影响。虽然这项收购旨在增强雅培在肿瘤诊断领域的市场地位，但预计会导致短期内的收益稀释。</p>
<p>公司还报告了 2026 年第一季度的财务结果，呈现出混合的局面。该季度的收入超过了分析师的预期。然而，调整后的摊薄每股收益符合共识预期，但略微低于一些预测。此外，某些部门，如营养部门，继续表现不佳，而快速和分子诊断部门由于呼吸病毒季节比去年轻微减弱而销售下降。</p>
<p>投资者的谨慎情绪还受到持续的法律和运营风险的影响。最近的陪审团裁决已命令雅培在诉讼中支付巨额赔偿，指控其婴儿配方奶粉导致坏死性小肠结肠炎。随着许多类似诉讼的待决，这种情况引发了对潜在未来财务责任的担忧，并影响了公司品牌形象，特别是在其营养部门。</p>
<p>分析师们也对这些发展做出了反应，一些公司下调了他们的目标价，尽管该股票的整体共识评级仍然大体积极，但这增加了投资者的谨慎情绪。</p>
<h2>雅培（ABT）的技术分析</h2>
<p>从技术上看，雅培（ABT）的 MACD（12,26,9）值为 [-2.41]，表明中性信号。RSI 为 37.33，表明中性状态，Williams %R 为-63.78，表明超卖状态。请密切关注。</p>
<h2>雅培（ABT）的基本面分析</h2>
<p>雅培（ABT）属于医疗服务与设备行业。其最新年收入为 443.3 亿美元，在行业中排名第三。净利润为 65.2 亿美元，在行业中排名第二。公司简介</p>
<p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png"/></p>
<p>在过去一个月中，多位分析师对该公司给予了买入评级，平均目标价为 132.05 美元，最高价为 158.00 美元，最低价为 113.00 美元。</p>
<h2>关于雅培（ABT）的更多细节</h2>
<p>公司特定风险：</p>
<ul>
<li>芝加哥陪审团最近裁定雅培在婴儿配方奶粉诉讼中赔偿总计 7000 万美元，包括 1700 万美元的惩罚性赔偿，指控其产品导致早产儿坏死性小肠结肠炎（NEC），全国范围内有超过 1700 个类似案件待决。</li>
<li>与婴儿配方奶粉相关的高调法律裁决可能会严重损害雅培的品牌声誉，特别是在其营养部门，可能导致消费者信心和市场份额下降。</li>
<li>雅培报告称 2026 年第一季度的 GAAP 净收益和摊薄每股收益大幅下降近 19%，主要归因于更高的运营成本和与其最近收购相关的费用。</li>
<li>公司的 2026 年全年调整后摊薄每股收益指引包括预计来自精密科学收购的 0.20 美元稀释，表明整合工作对财务的直接拖累。</li>
</ul>
<p>了解更多</p>

精密科学

雅培

基因改革 ETF - ARK

<p>雅培（Abbott Laboratories，股票代码：ABT）开盘下跌 4.34%，医疗服务与设备行业整体下滑 3.44%。此次下跌归因于修订后的盈利展望，因收购精密科学（Exact Sciences）预计将稀释收益，从而下调了 2026 年的每股收益（EPS）指引。尽管第一季度 2026 年的业绩超出收入预期，但表现参差不齐，持续的法律风险以及与婴儿配方奶粉相关的诉讼影响了品牌形象。分析师们下调了目标价，导致投资者情绪谨慎，尽管整体共识仍然积极</p>

<p>Abbott Laboratories (ABT) opened down by 4.34%. The Healthcare Services &amp; Equipment sector is down by 3.44%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Hims &amp; Hers Health Inc (HIMS) up 5.60%; Abbott Laboratories (ABT) down 4.34%; Danaher Corp (DHR) down 1.20%.</p>
<div class="lb-trans"><p>雅培（Abbott Laboratories，ABT）开盘下跌 4.34%。医疗服务与设备行业下跌 3.44%。该公司表现不及行业。该行业成交额前 3 的股票：Hims &amp; Hers Health Inc（HIMS）上涨 5.60%；雅培（ABT）下跌 4.34%；Danaher Corp（DHR）下跌 1.20%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png" alt="" original-src="https://resource.tradingkey.com/ai/wkrepot/f9e0e855-7c5e-4345-b35e-3edabb468113_1776347231.png"/></p>
<h2>What is driving Abbott Laboratories (ABT)’s stock price down today?</h2>
<div class="lb-trans"><h2>今天是什么原因导致雅培（ABT）股价下跌？</h2>
</div><p>Abbott Laboratories' stock experienced downward pressure today, primarily driven by a revised full-year earnings outlook. The company lowered its adjusted diluted earnings per share guidance for 2026, indicating an impact from its recent acquisition of cancer diagnostics firm Exact Sciences. While this acquisition is intended to strengthen Abbott's market position in oncology diagnostics, it is expected to result in a near-term earnings dilution.</p>
<div class="lb-trans"><p>雅培的股票今天承受了下行压力，主要是由于修订后的全年收益展望。公司下调了 2026 年的调整后摊薄每股收益指引，表明其最近收购癌症诊断公司精密科学（Exact Sciences）对业绩的影响。虽然这项收购旨在增强雅培在肿瘤诊断领域的市场地位，但预计会导致短期内的收益稀释。</p>
</div><p>The company also reported its first-quarter 2026 financial results, which presented a mixed picture. Revenue for the quarter surpassed analyst forecasts. However, adjusted diluted earnings per share met consensus estimates but slightly missed some predictions. Furthermore, certain segments, such as Nutrition, continued to show underperformance, and the Rapid and Molecular Diagnostics division experienced a decline in sales due to a less severe respiratory virus season compared to the prior year.</p>
<div class="lb-trans"><p>公司还报告了 2026 年第一季度的财务结果，呈现出混合的局面。该季度的收入超过了分析师的预期。然而，调整后的摊薄每股收益符合共识预期，但略微低于一些预测。此外，某些部门，如营养部门，继续表现不佳，而快速和分子诊断部门由于呼吸病毒季节比去年轻微减弱而销售下降。</p>
</div><p>Adding to investor caution are ongoing legal and operational risks. Recent jury verdicts have ordered Abbott to pay significant damages in lawsuits alleging that its infant formula caused necrotizing enterocolitis. With numerous similar lawsuits pending, this situation raises concerns about potential future financial liabilities and impacts the company's brand perception, particularly within its Nutrition segment.</p>
<div class="lb-trans"><p>投资者的谨慎情绪还受到持续的法律和运营风险的影响。最近的陪审团裁决已命令雅培在诉讼中支付巨额赔偿，指控其婴儿配方奶粉导致坏死性小肠结肠炎。随着许多类似诉讼的待决，这种情况引发了对潜在未来财务责任的担忧，并影响了公司品牌形象，特别是在其营养部门。</p>
</div><p>Analysts have also reacted to these developments, with some firms adjusting their price targets downwards, contributing to a cautious sentiment among investors, despite the overall consensus rating for the stock remaining largely positive.</p>
<div class="lb-trans"><p>分析师们也对这些发展做出了反应，一些公司下调了他们的目标价，尽管该股票的整体共识评级仍然大体积极，但这增加了投资者的谨慎情绪。</p>
</div><h2>Technical Analysis of Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>雅培（ABT）的技术分析</h2>
</div><p>Technically, Abbott Laboratories (ABT) shows a MACD (12,26,9) value of [-2.41], indicating a neutral signal. The RSI at 37.33 suggests neutral condition and the Williams %R at -63.78 suggests oversold condition. Please monitor closely.</p>
<div class="lb-trans"><p>从技术上看，雅培（ABT）的 MACD（12,26,9）值为 [-2.41]，表明中性信号。RSI 为 37.33，表明中性状态，Williams %R 为-63.78，表明超卖状态。请密切关注。</p>
</div><h2>Fundamental Analysis of Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>雅培（ABT）的基本面分析</h2>
</div><p>Abbott Laboratories (ABT) is in the Healthcare Services &amp; Equipment industry. Its latest annual revenue is $44.33B, ranking 3 in the industry. The net profit is $6.52B, ranking 2 in the industry. Company Profile</p>
<div class="lb-trans"><p>雅培（ABT）属于医疗服务与设备行业。其最新年收入为 443.3 亿美元，在行业中排名第三。净利润为 65.2 亿美元，在行业中排名第二。公司简介</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png" alt="" original-src="https://resource.tradingkey.com/ai/wkrepot/5c96fec5-fa27-4148-ae66-a54fccc01a79_1776347236.png"/></p>
<p>Over the past month, multiple analysts have rated the company as Buy, with an average price target of $132.05, a high of $158.00, and a low of $113.00.</p>
<div class="lb-trans"><p>在过去一个月中，多位分析师对该公司给予了买入评级，平均目标价为 132.05 美元，最高价为 158.00 美元，最低价为 113.00 美元。</p>
</div><h2>More details about Abbott Laboratories (ABT)</h2>
<div class="lb-trans"><h2>关于雅培（ABT）的更多细节</h2>
</div><p>Company Specific Risks:</p>
<div class="lb-trans"><p>公司特定风险：</p>
</div><ul>
<li>A Chicago jury recently awarded a total of $70 million, including $17 million in punitive damages, against Abbott Laboratories in infant formula lawsuits alleging its product caused necrotizing enterocolitis (NEC) in premature infants, with over 1,700 similar cases pending nationwide.</li>
<li>The ongoing high-profile legal verdicts related to infant formula have the potential to severely damage Abbott's brand reputation, particularly within its nutrition division, possibly leading to decreased consumer confidence and market share.</li>
<li>Abbott reported a significant nearly 19% decline in GAAP net earnings and diluted EPS for Q1 2026, primarily attributed to higher operating costs and charges related to its recent acquisition.</li>
<li>The company's full-year 2026 adjusted diluted EPS guidance includes a projected $0.20 dilution from the Exact Sciences acquisition, indicating an immediate financial drag from integration efforts.</li>
</ul>
<div class="lb-trans"><ul>
<li>芝加哥陪审团最近裁定雅培在婴儿配方奶粉诉讼中赔偿总计 7000 万美元，包括 1700 万美元的惩罚性赔偿，指控其产品导致早产儿坏死性小肠结肠炎（NEC），全国范围内有超过 1700 个类似案件待决。</li>
<li>与婴儿配方奶粉相关的高调法律裁决可能会严重损害雅培的品牌声誉，特别是在其营养部门，可能导致消费者信心和市场份额下降。</li>
<li>雅培报告称 2026 年第一季度的 GAAP 净收益和摊薄每股收益大幅下降近 19%，主要归因于更高的运营成本和与其最近收购相关的费用。</li>
<li>公司的 2026 年全年调整后摊薄每股收益指引包括预计来自精密科学收购的 0.20 美元稀释，表明整合工作对财务的直接拖累。</li>
</ul>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div>

Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know

TradingKey

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - SPDR

基因免疫&健康关怀 ETF - iShares

医疗业 ETF - Vanguard

美国医疗保健供应商 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做空 - Direxion

美国医药设备 ETF - iShares

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普健康医疗设备 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

Hims & Hers Health

丹纳赫

雅培公司股票（ABT）在 4 月 16 日开盘下跌 4.34%：投资者需要了解的事项